Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- Submitting institution
-
The University of Leeds
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- UOA2-2326
- Type
- D - Journal article
- DOI
-
10.1016/s2352-3026(19)30167-x
- Title of journal
- The Lancet Haematology
- Article number
- e616
- First page
- -
- Volume
- 6
- Issue
- 12
- ISSN
- 2352-3026
- Open access status
- Compliant
- Month of publication
- October
- Year of publication
- 2019
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
21
- Research group(s)
-
-
- Citation count
- 13
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Contribution A: Contribution to the organisation of the conduct of the study,Contribution to analysis and interpretation of the study data
Contribution B: The author helped draft the output,Critique the output for important intellectual content
- Non-English
- No
- English abstract
- -